March 19th 2024
"I am still struggling with disposing the scopes after each use, both from the environmental aspect and the fact that the scope technically can be used more than once," writes Gopal H. Badlani, MD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Water vapor ablation yields positive results at 2 years
September 8th 2017Treatment of lower urinary tract symptoms/BPH with convective water vapor ablation (Rezum System) appears to provide significant improvement on two key outcome measures versus medical therapy at up to 2 years, according to a study presented at the AUA annual meeting in Boston.
Gout patients at 60% greater risk for stone disease
September 4th 2017Men and women with gout are at 60% greater risk for nephrolithiasis than adults without gout, according to a study looking at not only the chronic kidney condition’s incidence but also potential risk factors for first-time nephrolithiasis in people with and without gout.
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drug
June 27th 2017Other pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
Urethral lift: 5-year data point to procedure’s durability
June 1st 2017Analyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.
Embolization for BPH shows long-term safety, efficacy
May 18th 2017Findings of a retrospective study including 1,000 men with follow-up ranging to 8 years demonstrate the long-term safety and efficacy of prostatic artery embolization for relieving lower urinary tract symptoms secondary to BPH, researchers reported at the Society of Interventional Radiology annual scientific meeting in Washington.
Urologists show low adherence to value-based care pathway
May 13th 2017Urologists’ adherence to value-based care pathways for BPH surgery is extremely low and only modestly improved when given individualized feedback on patient outcomes, costs, and practice patterns relative to peers, say UCLA researchers.
MRI, ultrasound detect post-burst wave lithotripsy injury
March 1st 2017Researchers who are investigating burst-wave lithotripsy, a potential alternative treatment for kidney stones, report that magnetic resonance imaging and ultrasound scans hold promise as tools to help scientists analyze related kidney injuries.